Plasmapheresis and intravenous immune globulin for the treatment of D alloimmunization in pregnancy.
The alloimmunized pregnancy can result in fetal and newborn mortality due to fetal anemia. Control of fetal anemia has not been possible until recently, and management consists of following the degree of fetal anemia during gestation until intrauterine transfusion is feasible to support the fetus until delivery. Cordocentesis and intrauterine transfusion have potential complications that have been well documented. Control of fetal anemia via immune modulation utilizing plasmapheresis and intravenous immune globulin administration has been attempted alone and in combination with varying results. We present a case report of an Rh(D) alloimmunized pregnancy, in which successful management consisted of initial therapeutic plasmapheresis (TPE) followed by intravenous immunoglobulin (IVIG) administration until delivery at 37 weeks gestation without the need for intrauterine transfusion.
Novak
Deborah J
DJ
Department of Pathology, Creighton University Medical Center, Omaha, Nebraska 68131, USA.
Tyler
Lisa N
LN
Reddy
Ramakrishna L
RL
Barsoom
Michael J
MJ
D000328:Adult; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D010956:Plasmapheresis; D011247:Pregnancy; D012203:Rh Isoimmunization / Q000628:therapy*; D012204:Rh-Hr Blood-Group System / Q000276:immunology; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D012204:Rh-Hr Blood-Group System; C026410:Rho(D) antigen